ORAMED PHARMACEUTICALS INC.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
ORMP$4.00+3.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $54,420 | $9,055 |
| Short-term deposits (note 2) | 55,281 | 95,279 |
| Marketable securities (note 3) | 3,441 | - |
| Investments at fair value (note 4) | 28,788 | 57,713 |
| Prepaid expenses and other current assets | 1,291 | 537 |
| Total current assets | 143,221 | 162,584 |
| LONG-TERM ASSETS: | ||
| Long-term deposits | 2 | 7 |
| Investments at fair value (note 4) | 7,387 | 51,035 |
| Marketable securities (note 3) | - | 1,807 |
| Other non-marketable equity securities (note 5) | 3,524 | 3,524 |
| Amounts funded in respect of employee rights upon retirement | 32 | 27 |
| Property and equipment, net | 698 | 873 |
| Operating lease right of use assets | 414 | 694 |
| Total long-term assets | 12,057 | 57,967 |
| Total assets | $155,278 | $220,551 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES: | ||
| Accounts payable and accrued expenses (note 6) | $5,140 | $1,609 |
| Short-term borrowings (note 7) | - | 51,013 |
| Payable to related parties (note 14b) | 329 | 325 |
| Operating lease liabilities | 216 | 267 |
| Total current liabilities | 5,685 | 53,214 |
| LONG-TERM LIABILITIES: | ||
| Long-term deferred revenues | 4,000 | 4,000 |
| Employee rights upon retirement | 30 | 28 |
| Provision for uncertain tax position (note 12f) | - | 11 |
| Operating lease liabilities | 156 | 342 |
| Other liabilities | 60 | 63 |
| Total long-term liabilities | 4,246 | 4,444 |
| COMMITMENTS (note 8) | ||
| EQUITY | ||
| EQUITY ATTRIBUTABLE TO COMPANY’S STOCKHOLDERS: | ||
| Common stock, $ 0.012 par value (60,000,000 authorized shares as of December 31, 2024 and December 31, 2023; 39,919,545 and 40,338,979 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively) | 480 | 485 |
| Additional paid-in capital | 322,401 | 320,892 |
| Accumulated deficit | (176,616) | (157,556) |
| Total stockholders’ equity | 146,265 | 163,821 |
| Non-controlling interests | (918) | (928) |
| Total equity | 145,347 | 162,893 |
| Total liabilities and equity | $155,278 | $220,551 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.